Log in

NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News

$36.87
-2.07 (-5.32 %)
(As of 02/24/2020 06:24 AM ET)
Today's Range
$36.72
Now: $36.87
$39.38
50-Day Range
$30.18
MA: $40.33
$43.50
52-Week Range
$13.80
Now: $36.87
$45.04
Volume1.08 million shs
Average Volume700,550 shs
Market Capitalization$2.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.59
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.86 per share

Profitability

Net Income$-127,500,000.00

Miscellaneous

Employees87
Market Cap$2.76 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.


Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.09. View Apellis Pharmaceuticals' Earnings History.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Apellis Pharmaceuticals.

What price target have analysts set for APLS?

10 brokerages have issued 12 month price objectives for Apellis Pharmaceuticals' stock. Their forecasts range from $23.00 to $80.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $46.09 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

What is the consensus analysts' recommendation for Apellis Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

What are Wall Street analysts saying about Apellis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (2/19/2020)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating on Apellis and lowering our 12-month price target to $52 from $57. This morning, Apellis issued a press release highlighting financial and corporate updates for the period ended on 3/31. Our decrease in price target is based off an increased share count, due to the recent March 2019 financing, and an increase to R&D and SG&A projections. With Phase 3 PEGASUS (PNH) enrollment expected to complete by the end of 2Q19, we believe APLS shares represent a strong buying opportunity, ahead of a potential 4Q19 data readout. Below we revisit our thoughts on APL-2 and its potential to be a disruptive addition to the PNH market." (5/8/2019)

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Headlines about APLS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Apellis Pharmaceuticals.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,670,000 shares, an increase of 22.4% from the January 15th total of 5,450,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 4.9 days. Approximately 12.6% of the shares of the company are sold short. View Apellis Pharmaceuticals' Current Options Chain.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
  • Mr. Ahmad Sadr, VP of Technical Operations

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (3.10%), State Street Corp (3.07%), Victory Capital Management Inc. (2.90%), FIL Ltd (1.86%), Barclays PLC (1.55%) and Jennison Associates LLC (1.48%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Fiduciary Trust Co., Jane Street Group LLC, SG Americas Securities LLC, Candriam Luxembourg S.C.A., Pictet Asset Management Ltd., Baird Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois and Pascal Deschatelets. View Insider Buying and Selling for Apellis Pharmaceuticals.

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Victory Capital Management Inc., Farallon Capital Management LLC, Victory Capital Management Inc., FIL Ltd, FMR LLC and Bank of Montreal Can. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $36.87.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $2.76 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel